Thalidomide as a treatment for refractory CGD colitis

American Journal of Gastroenterology

Volumn 104, Issue 4, 2009, Pages 1069-1070

  Sokol, Harry ^a   Suarez, Felipe ^b   Meatchi, Tchao ^c   Malamut, Georgia ^c   Pocidalo, Marie Anne ^a   Blanche, Stephane ^b   Cellier, Christophe ^c   Hermine, Olivier ^b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; COTRIMOXAZOLE; CYCLOSPORIN; HYDROXYCHLOROQUINE; INFLIXIMAB; ITRACONAZOLE; MESALAZINE; PREDNISONE; SALAZOSULFAPYRIDINE; THALIDOMIDE; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; BACTERIAL INFECTION; CASE REPORT; CHRONIC GRANULOMATOUS DISEASE; CLINICAL FEATURE; COLITIS; CROHN DISEASE; DIARRHEA; DRUG TREATMENT FAILURE; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; INFECTION RISK; LETTER; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SALMONELLOSIS; SIDE EFFECT; BIOPSY; COMPLICATION; DIFFERENTIAL DIAGNOSIS; FOLLOW UP; GRANULOMATOUS DISEASE, CHRONIC;

BIOPSY; COLITIS; DIAGNOSIS, DIFFERENTIAL; FOLLOW-UP STUDIES; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; THALIDOMIDE;

EID: 65449162715     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.56     Document Type: Letter

References (7)

1. Hatanaka E, Carvalbo BT, Condino-Neto A et al. Hyperresponsiveness of neutrophds from gp 9lphox deficient patients to hpopolysaccharide and serum amyloid A. Inimunal. Lett 2004;94: 43-6.
2. Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999;58 (Suppl 1): 1107-13.
3. Nielsen H, valeriuc NH. Thalidnmide enhances superoxide anion release from human polymorphonuclear and mononuclear leukocytes. Acta Pathal. Microbial. Immunal. Scand [C] 1986;94:233-7.
4. Muniz-Junqueira MI, Silva FO, de Paula-Junior MR et al. Thalidomide influences the function of macrophages and increases tbe survival of Plasmodium berghei-infected CBA mice. Acta Trop 2005;94:128-38.
5. Sabate JM, Villarejo L Lemann M et al. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractor) Crohn's disease. Aliment Pharmacal. Ther 2002;t6:ttt7-24.
6. Hayee B, Rahman F, Marks DJ et al. The prevalence of undiagnosed disorders of neutrophil function mimicking Crohn's disease. Gastroenterology 2008; t34 (Suppl 1): A-t4.
7. Kyriakou C, Thomson K, D Sa S et al. Low-dose thalidomide in combination with oral weekly cyclophosphamtde and pulsed dexametbasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br f Haematol 2005: t29:763-70.